视频

Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome

 

Authors Hanna AF, Abraham B, Hanna A, Smith AJ

Received 25 March 2017

Accepted for publication 11 May 2017

Published 18 August 2017 Volume 2017:10 Pages 305—308

DOI https://doi.org/10.2147/IMCRJ.S137975

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Ronald Prineas

Abstract: Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption.
Keywords: chronic Lyme, late Lyme, pain, analgesic, suicidality, depression


 

摘要视频链接Ketamine for post-treatment Lyme disease